RETRACTED: MiR‐137 functions as a tumor suppressor in pancreatic cancer by targeting MRGBP

Abstract

miRNAs are small noncoding RNAs that act as critical epigenetic regulators in tumor carcinogenesis. In this study, our data showed that miR-137 was significantly downregulated in 58 pairs of human pancreatic cancer (PanCa) tissues and PanCa cell lines. Furthermore, the deregulated miR-137 was correlated with increased tumor size, higher TNM stage, and worse prognosis in pancreatic cancer. Functional studies demonstrated that overexpression of miR-137 dramatically suppressed cell proliferation and induced cell apoptosis in vitro. Meanwhile, upregulated miR-137 remarkably inhibited migration and invasion of pancreatic cancer cells. Further studies indicated that MRGBP was identified as the direct downstream target gene of miR-137. In addition, MRGBP expression is significantly downregulated in miR-137-transfected cells. Our previous study revealed that silencing of MRGBP suppressed the growth of PanCa cells in vitro and in vivo and also promoted apoptosis, and inhibited migration and invasion of PanCa cells, which are consistent with the effects of miR-137 overexpression. Taken together, our findings suggest that miR-137 may function as a novel tumor promoter through directly targeting MRGBP in PanCa.

Identifying Key Genes for Nasopharyngeal Carcinoma by Prioritized Consensus Differentially Expressed Genes Caused by Aberrant Methylation

“…Upregulation of the miR-34 family resulted in apoptosis and cell-cycle arrest through targeting p53 [32,33]. MIR152 and MIR137 inhibited cell proliferation, migration, and invasion in human cancers [34][35][36][37]. Downregulation of MIR129-2 by promoter hypermethylation induced breast cancer cell proliferation and apoptosis [38].…”

Hypoxia and Selective Autophagy in Cancer Development and Therapy

“…This characteristic could render CNX a valuable prognosis marker (Lakkaraju and van der Goot, 2013 ; Kobayashi et al, 2015 ; Ryan et al, 2016 ; Ma et al, 2017 ). On the other hand, miR-137 acts as a tumor suppressor as evidenced in various cancer cell types (Neault et al, 2016 ; Chen T. et al, 2017 ; Ding F. et al, 2018 ). Finally, the role of the PINK1/Parkin pathway in cancer onset and progression has already been extensively reviewed (Lu et al, 2013 ; Matsuda et al, 2015 ; Eid and Kondo, 2017 ; Palikaras et al, 2017 ).…”

miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4

“…Abnormal miRNA expression has also been identified in BC and is closely correlated with proliferation, invasion, metastasis, and chemoresistance 13,14 . miR-137 is frequently downregulated in some solid tumors, including colon cancer 15 , non-small cell lung cancer 16 , pancreatic cancer 17 , gastric cancer 18 , and osteosarcoma 19 , and potentially acts as a tumor suppressor in these tumors. Though miR-137 is involved in chemoresistance in several cancers [20][21][22] , its physiological role in DOX resistance of BC is not well elucidated.…”